GHK-Cu Research: What the Studies Actually Show

Clear glass vials on a steel bench, one containing a blue copper-complex solution, with a faint coordination diagram and chromatogram trace behind them

Most of what circulates about this compound is downstream of a handful of papers. This review walks through the primary GHK-Cu research the way a reader evaluating a reagent would: what the published studies measured, in which model, who published them, and where the record runs out. It is a literature review of a catalogue compound, not a guide to using one.

What the molecule is

GHK is the tripeptide glycyl-histidyl-lysine. GHK-Cu is its copper(II) complex: the peptide coordinates a copper ion, and the complex rather than the free tripeptide is generally what the literature discusses. The histidine imidazole and the peptide backbone nitrogens provide the coordination environment, which is why copper binding is treated as intrinsic to the molecule's identity rather than an additive. GHK was first reported in human serum by Pickart and Thaler, 1973, and later reviews describe it as present in plasma, saliva and urine. That is the whole of the identity question, and it is the least contested part of the file.

GHK-Cu research, study by study

1973: the original serum observation

The founding paper (Pickart and Thaler, 1973) was a cell-culture study, published in Nature New Biology, reporting that a tripeptide isolated from human serum prolonged the survival of normal liver cells in culture and stimulated growth in neoplastic liver cells. Two things are worth reading carefully there. First, the model is hepatocytes in culture, not skin and not an intact animal. Second, the reported behaviour was not uniformly “regenerative” — the same paper describes growth stimulation in a neoplastic model. Half a century of secondary writing has narrowed that observation considerably.

Matrix chemistry: collagen, glycosaminoglycans, metalloproteinases

The largest body of copper peptide research concerns extracellular matrix turnover in vitro. Review coverage of this work (Pickart et al., 2015) collects laboratory reports of effects on collagen and glycosaminoglycan synthesis and on metalloproteinase activity in fibroblast systems. These are biochemical endpoints measured in cell and tissue preparations. They describe what the complex does to a culture system; they do not establish what happens in an organism, and the reviews themselves do not supply that bridge.

Gene-expression profiling

The second substantial strand is transcriptional. A later review (Pickart and Margolina, 2018) is built around broad gene-expression data — the observation that exposure to the peptide shifts the expression of a large number of genes in profiling experiments. This is the most frequently over-read result in the field. Broad expression changes in a profiling dataset are a hypothesis-generating signal: they identify pathways worth testing. They are not themselves evidence of an outcome in tissue, and the step from a differential-expression list to a physiological claim is exactly the step the published record has not taken.

Animal wound models and cosmetic skin studies

Animal skin-healing models and topical cosmetic skin studies make up the remaining research areas described for the compound. The animal work sits in the standard preclinical category: a defined injury model, a defined readout, small group sizes. The cosmetic literature is reported at the level of product formulations rather than the isolated complex, which matters for interpretation — a finished formulation differs from a characterised reagent in concentration, vehicle and stability. No independent controlled clinical trial of GHK-Cu was located in the sources underlying this review.

Where the evidence stops

Four limits define the file:

  • Model ceiling. The evidence is mainly laboratory and animal work plus cosmetic-formulation studies. Mechanistic descriptions of the complex do not transfer to predictions about people, and the reviews do not claim they do.
  • Mechanism is proposed, not settled. The copper complex has been proposed as the active form. Proposed is the operative word; the causal chain from copper coordination to matrix or transcriptional readout is not closed.
  • Source concentration. Many of the reviews come from the discoverer's group, which has commercial ties — the 2015 and 2018 review affiliations are a skin-care research and development company. That does not make the data wrong, but a field whose synthesis literature is largely written by one interested group has not been independently stress-tested, and the broader claims made in those reviews are not repeated here.
  • Human safety data are thin. FDA's compounding review of bulk substances notes limited human data for this substance; the agency's bulk drug substances page is the primary document on that point.

The honest summary: a well-characterised small molecule with a long in-vitro literature, a plausible coordination chemistry story, a concentrated authorship base, and no controlled human evidence to review.

How a lot is characterised

Because the compound is a copper complex, lot documentation answers two questions rather than one: is the peptide sequence correct, and is the complex intact. Reverse-phase HPLC resolves the main peak from process-related impurities and gives the chromatographic identity and the measured purity for that lot; mass spectrometry confirms the molecular mass against the expected value for the tripeptide and its copper adduct. Each lot's certificate of analysis states the measured purity and identity for that specific lot — the certificate, not a catalogue figure, is the document that applies to the vial in hand.

Appearance is a weak but real signal for this compound: the complex is characteristically blue, and a lyophilised cake that has lost that colour is worth querying against the certificate rather than assuming. Storage for the catalogue item is −20 °C, desiccated and protected from light; copper complexes are both light- and moisture-sensitive, so the desiccated and light-protected conditions are not boilerplate.

Specification

FieldValue
Catalogue nameGHK-Cu
IdentityCopper(II) complex of glycyl-histidyl-lysine
CategoryCopper & cosmetic
FormatLyophilised powder, glass vial, crimp seal, flip-top cap
House codesCS-GHK-50 (50 mg), CS-GHK-100 (100 mg)
Storage−20 °C, desiccated, protect from light
Lot documentationRP-HPLC identity and measured purity, mass-spectrometric mass confirmation, per lot
Evidence stageMostly preclinical; cell, animal and cosmetic-formulation literature

Where it appears in blends

GHK-Cu is the largest component by mass in two catalogue blends: the CS-GLW blend (with BPC-157 and TB-500) and the CS-KLW blend (the same three plus KPV). Nothing in the published literature examines those combinations as combinations — each component has its own separate file, and the evidence for a mixture is not the sum of the evidence for its parts. We compare the two component lists, and the state of the evidence behind each, in CS-GLW and CS-KLW blends compared. For an adjacent example of how far a receptor-level mechanism can be documented while outcome evidence stays absent, see our PT-141 receptor pharmacology review.

Frequently asked questions

What does GHK-Cu research actually consist of?

Cell-culture work on matrix turnover and gene expression, animal skin-healing models, and cosmetic-formulation skin studies, built on a 1973 report of the tripeptide in human serum. There is no controlled clinical trial literature to review.

Why is the copper part emphasised?

Because the published work treats the copper(II) complex, not the free tripeptide, as the species of interest — the complex has been proposed as the active form. Characterisation and storage conditions follow from that: the molecule is a metal complex and is handled as one.

Is the evidence base independent?

Partly. The primary observations are distributed, but a large share of the review literature comes from the discovering group, which has commercial ties. That concentration is a reason to read the synthesis papers more sceptically than the primary data.

What does the certificate of analysis tell me?

It states the measured purity and identity for the specific lot, by RP-HPLC with mass-spectrometric confirmation. It is lot-specific, which is why it is the document to read rather than a general catalogue specification.

See it in the catalogue: GHK-Cu.

For laboratory research use only. Products sold by California Standard Peptides are not drugs, foods, supplements or cosmetics and are not for human or veterinary use. This article summarises published literature; it is not medical advice and not a usage guide.

California Standard Peptides

Your cart

0 items · free shipping over $200.00

Your cart is empty.

Buy 2 of a vial and save 10%, 3 and save 15%. Research sets are 15% off, and shipping is free over $200.00.

First order

20% off your first order.

Join the list for first word on new lots, restocks and member pricing. Your code arrives by email and applies by itself at checkout.

One code per email, for your first order. By signing up you agree to get emails from us. Unsubscribe anytime.

For laboratory research use only. 21+.